DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Keratol Nail Gel (Urea Topical) - Summary

 
 



SUMMARY

DESCRIPTION: KeratolTM 45 Nail Gel, is a keratolytic emollient, which is a gentle, yet potent, tissue softener for nails and/or skin.   Each gram of KeratolTM 45 Nail Gel contains 45% Urea, camphor, edetate disodium, eucalyptus oil, hydroxyethyl Cellulose, menthol, propylene glycol and purified water.

Keratol is indicated for the following:

For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly when healing is retarded by local infection, necrotic tissue, fubrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails.


See all Keratol Nail Gel indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Keratol Nail Gel (Urea Topical)

Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream. [2011.12]
Abstract Background: Ichthyoses are genetic disorders of keratinization which are uncomfortable due to their conspicuous scaling, itching and cosmetic problems.Further studies with larger sample sizes are needed for the evaluation of safety and tolerability of urea 10% lotion in this clinical setting.

Clinical evaluation of 35% urea in a water-lipid-based foam containing lactic acid for treatment of mild-to-moderate xerosis of the foot. [2011.03]
BACKGROUND: We evaluated 35% urea in a water-lipid-based foam delivery system containing lactic acid in participants with mild-to-moderate xerosis of the foot... CONCLUSIONS: Thirty-five percent urea in a water-lipid-based foam delivery system containing lactic acid can be an appropriate treatment option for mild-to-moderate xerosis of the foot.

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. [2010.12.10]
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS... CONCLUSION: These data do not support the efficacy of a ULABTKA cream for preventing HFS symptoms in patients receiving capecitabine.

Efficacy and safety of a new topical keratolytic treatment for localized hyperkeratosis in adults. [2010.12]
BACKGROUND: Palmoplantar keratoderma (PPK) is a heterogeneous group of skin disorders characterized by symmetrical diffuse or patchy areas of hyperkeratosis on the palms and soles. This study aimed to evaluate the efficacy and safety of a topical keratolytic treatment for localized hyperkeratosis... CONCLUSION: This topical keratolytic treatment represents a valuable first-line option for mild to moderate hyperkeratosis.

Efficacy and safety of a new topical keratolytic treatment for localized hyperkeratosis in adults. [2010]
topical keratolytic treatment for localized hyperkeratosis... CONCLUSION: This topical keratolytic treatment represents a valuable first-line

more studies >>

Clinical Trials Related to Keratol Nail Gel (Urea Topical)

Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis [Recruiting]
Dose response curve to define the security and tolerable dose to be used for prevention and treatment of radiodermatitis in patients with breast or head and neck cancer.

Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment [Completed]
In this short-term study a method for the evaluation of the metabolic competency of the urea cycle in vivo will be assessed. In order to monitor the efficacy of new treatment options for patients with urea cycle disorders and to monitor the severity of the disease, a reliable and safe quantitative method for the measurement of the urea cycle flux is required. Urea synthesis will be evaluated by administering sodium [1-13C]-acetate and measuring subsequent incorporation of [13C] label from Na-acetate into urea in healthy volunteers and asymptomatic subjects genetically disposed to urea cycle disorders.

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function [Completed]
This diagnostic study will be performed to investigate the performance of the urea cycle in healthy subjects, asymptomatic carriers of Urea Cycle Disorders (UCD) mutations and subjects with genetically proven urea cycle disorders. The ureagenesis rate will be measured by 13C incorporation assay, a method for in vivo measurement of urea cycle performance with stable isotopes.

Vaginal Fluid Wash in Pre-labour Rupture of Membranes [Recruiting]
The investigators assess in this study the sensitivity of Urea and Creatinine and that of Nitrazine test in vaginal wash after injecting saline in the vagina of patients with pre-labour rupture of membranes

Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis [Not yet recruiting]
This study aims to evaluate therapeutics interventions in radiodermatitis in patients with breast or head and neck cancer. The data collect is going to begin after determining the better dose in a dose-response curve that is being conduct now in the same institution. To evaluate the skin reaction will be applied scale of the Radiation Therapy Oncology Group

(RTOG) - Acute Radiation Morbidity Scoring Criteria, Common Terminology Criteria for Adverse

Events (CTCAE) and Radiation-Induced Skin Reaction Assessment Scale (RISRAS).

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015